Day One Biopharmaceuticals, Inc. financial data

Symbol
DAWN on Nasdaq
Location
2000 Sierra Point Parkway, Suite 501, Brisbane, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 897 % +3.89%
Quick Ratio 8.95 %
Debt-to-equity 13.5 % +2.58%
Return On Equity -32.1 % -43.1%
Return On Assets -28.2 % -42.7%
Operating Margin -124 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 103M shares +1.81%
Common Stock, Shares, Outstanding 103M shares +1.85%
Entity Public Float 972M USD +28.1%
Common Stock, Value, Issued 10K USD 0%
Weighted Average Number of Shares Outstanding, Basic 103M shares +6.99%
Weighted Average Number of Shares Outstanding, Diluted 103M shares +6.65%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 134M USD -57.6%
Research and Development Expense 169M USD -16.8%
General and Administrative Expense 116M USD +7.69%
Operating Income (Loss) -166M USD +21.7%
Nonoperating Income (Expense) 20.3M USD -30.6%
Income Tax Expense (Benefit) 6.47M USD
Net Income (Loss) Attributable to Parent -152M USD -80%
Earnings Per Share, Basic -1 USD/shares -43.1%
Earnings Per Share, Diluted -1 USD/shares -43.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 43.3M USD -89.8%
Inventory, Net 7.06M USD +158%
Other Assets, Current 322M USD +20.6%
Assets, Current 490M USD -15.7%
Property, Plant and Equipment, Net 2.23M USD +146%
Operating Lease, Right-of-Use Asset 2.45M USD -4.82%
Assets 514M USD -14.5%
Accounts Payable, Current 5.78M USD +91.5%
Liabilities, Current 56.5M USD +42.1%
Operating Lease, Liability, Noncurrent 2.73M USD +7.64%
Other Liabilities, Noncurrent 761K USD
Liabilities 62.9M USD +38.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 69K USD
Retained Earnings (Accumulated Deficit) -640M USD -31.1%
Stockholders' Equity Attributable to Parent 451M USD -18.8%
Liabilities and Equity 514M USD -14.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -59M USD -18.6%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities -32.6M USD -137%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 103M shares +1.85%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 43.3M USD -89.8%
Deferred Tax Assets, Valuation Allowance 155M USD +64.7%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 157M USD +66.4%
Operating Lease, Liability 2.89M USD +10.6%
Payments to Acquire Property, Plant, and Equipment 317K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -152M USD -79.9%
Lessee, Operating Lease, Liability, to be Paid 4.45M USD -0.18%
Property, Plant and Equipment, Gross 243K USD +106%
Operating Lease, Liability, Current 161K USD +109%
Lessee, Operating Lease, Liability, to be Paid, Year Two 543K USD +24.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 527K USD +49.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Deferred Income Tax Expense (Benefit) 900K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.56M USD -15.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 492K USD +9.82%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 6.37M USD +142%
Lessee, Operating Lease, Liability, to be Paid, Year Four 711K USD +54.2%
Operating Lease, Payments 4.4M USD
Additional Paid in Capital 1.09B USD +4.51%
Amortization of Intangible Assets 2.9M USD +33.3%
Depreciation, Depletion and Amortization 94K USD +309%
Share-based Payment Arrangement, Expense 44.4M USD -7.67%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%